Three (12.0%) patients transformed to diffuse large B-cell lymphoma (DLBCL) ranging from 7.8 to 25.8 months after initiating BR and were subsequently treated with R-CHOP. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.